SMMT vs. MRK, TAK, ARGX, ONC, INSM, BNTX, TEVA, GMAB, RDY, and ASND
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Merck & Co., Inc. (MRK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Summit Therapeutics vs. Its Competitors
Summit Therapeutics (NASDAQ:SMMT) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.
Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Merck & Co., Inc. has a net margin of 25.79% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 41.05% beat Summit Therapeutics' return on equity.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Comparatively, 0.1% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summit Therapeutics presently has a consensus price target of $32.40, suggesting a potential upside of 77.44%. Merck & Co., Inc. has a consensus price target of $106.41, suggesting a potential upside of 30.78%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..
In the previous week, Merck & Co., Inc. had 67 more articles in the media than Summit Therapeutics. MarketBeat recorded 91 mentions for Merck & Co., Inc. and 24 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.42 beat Summit Therapeutics' score of 1.04 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.
Summit Therapeutics has a beta of -1.02, suggesting that its share price is 202% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Summary
Merck & Co., Inc. beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SMMT) was last updated on 9/18/2025 by MarketBeat.com Staff
